Company ProfilePremium

Shenguan Holdings (Group) Limited

Company Profile Analysis

Ticker: 0829.HK神冠控股

ESOMAR 23 Corporate BadgeISO Certifications Badge
Shenguan Holdings (Group) Limited - Company showcase

Year Founded & Workforce

1979

2,793 Employees

Shenguan Holdings (Group) Limited logo

Shenguan Holdings (Group) Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Shenguan Holdings (Group) Limited Overview

Shenguan Holdings is China's pioneer and largest domestic manufacturer of edible collagen sausage casings, a niche but essential input for the industrial sausage, ham-sausage and processed-meat industry. Built on four decades of proprietary collagen-extraction technology from bovine inner skin in Wuzhou, Guangxi, the Group supplies leading Chinese meat processors and exports to Southeast Asia, South America and the United States. Collagen casings still generate over 90% of revenue, but the Group has spent five years pursuing a "Three Developments and One Core" diversification into collagen foods, collagen skincare and polymer collagen medical biomaterials. The company is in a difficult transition: a 2024 casing-product overhaul (six "S-series" lines) has gained share but left a legacy-inventory overhang that drove FY2025 and 1H2026 losses. With a net-cash balance sheet, a founder-controlled shareholder base, minimal analyst coverage and a share price that has collapsed roughly 94% from its 2009 IPO, Shenguan is a deep-value, high-execution-risk turnaround situation.


Company's Own Description (FY2025 Annual Report, paraphrased)

In its FY2025 Annual Report and Results Announcement, the company describes itself as an investment holding company whose subsidiaries are principally engaged in the manufacture and sale of edible collagen sausage casing products, collagen food products, collagen skincare products and polymer collagen medical biomaterials. It states that more than 90% of Group revenue derives from edible collagen sausage casings, which is why it presents a single reportable operating segment. Management frames its long-run strategy as using "core collagen technology" as an engine for diversified applications, with sausage casings as the cash-generating core and the "grand health industry" (foods, skincare, medical) as the second growth curve.

What the Company Actually Does

Shenguan converts bovine inner skin (the corium layer of cattle hides, sourced largely from Guangxi suppliers including a related party, Guangxi Zhiguan Industrial Development) into purified collagen, which is extruded into continuous tubular casings. Casings are sold by the metre (in shirred sticks/reels) to sausage manufacturers who stuff them on high-speed automated lines. Edible collagen casings substitute for natural (animal intestine) casings, offering calibre uniformity, hygienic consistency and machine-ability, and compete with cellulose, plastic and co-extruded alginate alternatives.

The value chain position is mid-stream B2B ingredient/packaging-component supply:

Upstream: cattle inner-skin suppliers (highly concentrated; top supplier 67.7% of FY2025 purchases), packaging materials (partly from related-party Wuzhou Junye Printing Material), energy (≈RMB183.7m in FY2025 cost of sales) and labour.

Midstream (Shenguan): collagen extraction, casing extrusion, drying, shirring, QC (including in-house accredited testing subsidiary Guangxi Wuzhou Zhongguan Testing Technology Services).

Downstream: Chinese ham-sausage, Western-style sausage, grilled/fried sausage and snack-sausage producers; export distributors (e.g., Malaysia via the non-executive founder's Exceltech Food Trading).

Revenue Model

Revenue typeApprox. weightNotesSource
Product sales — edible collagen casings>90% of revenueRecognised at a point in time; volume × price per metreFY2025 Results, Note 3–4
Product sales — collagen food, skincare, medical collagen raw materials<10% (exact figure n.d.)Grew 44.1% in FY2025; medical biomaterials declined 31.5% in 1H2026FY2025 AR; 2026 Interim
Services (testing, other)RMB0.495m in FY2025 (0.05%)Third-party testing by Wuzhou ZhongguanFY2025 Results, Note 4
Subscription / licensing———
Other income (outside revenue)RMB34.1m FY2025Bank interest RMB15.4m, government grants RMB9.0m, rent RMB4.4m, auxiliary material sales RMB4.6mFY2025 Results, Note 4

Customer Types and End-Markets

Industrial meat processors (core): large Chinese ham-sausage and sausage brands. Customer concentration has fallen: two customers each exceeded 10% of revenue in FY2021–FY2023 (FY2023: RMB206.2m and RMB122.9m, together ≈29.6% of revenue), but no customer exceeded 10% in FY2024 or FY2025. In FY2025, the top five customers were 29.1% of sales and the largest 8.3% (FY2025 AR, Report of the Directors).

Export customers: Asia ex-mainland (8.4% of FY2025 revenue) and other regions (3.7%), including Southeast Asia, South America and the US (company is FDA-registered for casing exports). A halal market push was described in 1H2026 as making "phased progress".

Consumer (B2C) channels: collagen foods and skincare sold via e-commerce, live-streaming and offline channels (brands Luxianna, COLL-FULL/高肌樂, Collagen Family, coll-shine).

Medical/biomaterial customers: buyers of medical-grade collagen raw material (domestic and export; affected by tariffs/trade friction in 1H2026).

Independent Characterisation

Shenguan is effectively a single-product industrial supplier with a dominant domestic position that peaked in profitability around 2012–2013 and has since been squeezed by (i) price competition and capacity additions in China, (ii) margin pressure from raw-material, energy and labour inflation, (iii) a costly, multi-year production-line overhaul (200→300 lines in 2023; capacity ~7bn metres by 2024), and (iv) diversification projects that remain sub-scale. The FY2024 product relaunch appears commercially successful at the volume level (new S-series reached 43% of casing sales in 1H2026, up from 31%), but the accounting for the transition (inventory provisions of RMB46.4m in FY2025 and RMB46.7m in 1H2026 alone) has turned the Group loss-making. The business is better described today as a "restructuring incumbent" than a growth company.

Strategy

Stated Strategy (FY2025 AR and 2026 Interim, paraphrased)

  1. "Three Developments and One Core" (since the 13th Five-Year Plan): collagen technology as the core, with development in collagen food, collagen skincare and polymer collagen medical biomaterials. The FY2025 AR frames this as building a "second growth curve".

  2. 2026 operating theme: "Ensuring Quality, Stabilising Production, Strengthening Management and Clarifying Responsibilities" (FY2025 AR). In practice this means (a) accelerating high-end S-series production lines and digital/intelligent capability to address a stated shortfall in high-end capacity; (b) stabilising process and quality standards across the six S-series lines; (c) securing raw materials, maintaining equipment and improving line uptime.

  3. Clean-label and high-end thesis (2026 Interim): management argues that regulation (GB 31661-2025 on prepared meat hygiene, GB 2760-2024 on food additives, GB 7718-2025 on labelling effective 2027, T/CAS1082-2025 clean-label standard) plus a shift toward large-calibre, high-meat-content sausages will increase demand for medium-to-large-calibre high-end collagen casings and natural-ingredient fillers. It states it has phased out old low-end lines in favour of new high-end medium-to-large-calibre lines.

  4. Collagen compound ingredients: positioned as a low-capex adjacency reusing equipment, technology and food sales channels, building on Guangxi's spice-sourcing advantage.

  5. Working-capital discipline (2H2026): a precise sales plan for finished casings, rigid inventory targets, a review of spare-parts stock, yield improvement and reduction of rework.

  6. International: a halal-market focus with overseas halal filings and expansion of halal production lines.

  7. 15th Five-Year Plan: the Group is reviewing processes to set a medium- and long-term blueprint (not yet published).

Initiatives Announced in the Last 24 Months (Oct 2024 – Oct 2026)

InitiativeDateScopeTargets / status
S-series product ramp (six lines)Launched Q2 2024; ongoingConvert customers from legacy casingsOver 40% of FY2025 casing volume; 43% of 1H2026 casing sales; S-series sales RMB197m in 1H2026 (+47%)
"Intelligent Digital Control Innovation Project for Sausage Casings"Core priority 2026Process/equipment R&D, automation, intelligent upgrade of high-end linesVerification results achieved 1H2026; capex budget RMB120m for 2026
Inventory clean-up / volume-for-margin strategy2H2025 – 2026Discount legacy-process and trial-run finished goodsProvisions RMB46.4m FY2025, RMB46.7m 1H2026
Collagen compound ingredientsCommercialised 2025–2026Clean-label sausage fillersRevenue n.d.
Inner Mongolia (Horinger) production base13 Aug 2026~219 mu land; collagen raw material prep, food processing, casings~RMB90m; non-binding; subject to land auction
Halal market expansion2024–2026Certifications; halal lines"Phased progress" in 1H2026
Medical device licensingOngoingArtificial bone (Class III), dental collagen spongeApplications advancing; no approvals announced as of Aug 2026
Workforce Diversity PolicyAdopted 30 Mar 2026Group-wideMaintain ~38% female workforce
Dividend and Nomination Policy amendments30 Mar 2026GovernanceDividend now explicitly conditioned on profitability and stability
Automation to offset labour costOngoingReduce headcount relianceHeadcount 3,070 (FY2024) → 2,793 (1H2026)

Medium-Term Financial Targets / Guidance

No quantitative revenue, margin or return targets have been published. The only quantified forward guidance is FY2026 capex of approximately RMB120.0m (FY2025 AR; reaffirmed in the 2026 Interim, now also covering the Inner Mongolia base). Management has also stated it will implement stricter inventory controls in 2H2026.

Products & Services

Collagen Sausage Casings (core)

ProductDescription / capabilitiesTarget customerLaunch / latestPricing
"Fried" (炸) seriesS-series casing engineered for frying applications; FY2025 quality-stabilisation prioritySnack/fried-sausage makersLaunched 2024—
"Crispy" (脆) seriesS-series casing for snap/bite texturePremium sausage brands2,024—
"Fresh" (鮮) seriesS-series casing for fresh sausage; FY2025 priority productFresh sausage processors2,024—
"Tender" (嫩) seriesS-series casing for tender-bite productsSausage processors2,024—
"Bright" (亮) seriesS-series casing with appearance/gloss characteristicsRetail-facing brands2,024—
"Colorful" (彩) seriesS-series coloured casingSpecialty/retail2,024—
Medium/large-calibre casingsHigh-toughness, high-adhesion casings for large-calibre high-end sausages and Western-style hams; flagged as the key demand driver in 1H2026High-meat-content sausage producersExpanded 2022–2026; new lines under "Intelligent Digital Control Innovation Project"—
Small-calibre casingsTraditional high-volume casingsMass-market ham-sausageLegacyn.d.; legacy stock discounted in 2H2025–1H2026
Imitation high-end natural casingsCollagen casings replicating natural-casing appearance/bitePremium segmentDeveloped ~2021—
Halal collagen casingsCertified by Halal Foundation Center / Shaanxi International Halal Certification Center (2024) and SSPY International Halal Certificate (2025)Muslim-majority export markets, domestic halal2024–2025—

Capacity: ~7 billion metres (FY2024 Results). Production lines: ~300 after 2023 overhaul, with 50 additional lines planned in 2024 (FY2023 Results). Standards: GB14967-2015 (national), SB/T10373-2012 (industry); ISO9001, ISO22000, ISO10012, ISO45001, ISO14001; US FDA registration.

Collagen Compound Ingredients (new)

ProductDescriptionTargetStatus
Collagen compound ingredients (sausage fillers)Low-fat, high-protein functional ingredient enabling "clean label" sausage formulations; leverages existing equipment and food channelsMeat processors responding to GB 2760-2024, GB 7718-2025, GB 31661-2025 and clean-label standardsDescribed as "recently commercialised" key project (FY2025 AR); revenue n.d.

Collagen Food Products

ProductDescriptionLaunch/latestPricing
Ready-to-eat beef tendonSnack foodUpgraded 2024Retail, n.d.
Beef tripe (牛西肚)Ready-to-eatLaunched 2024—
Bo Bo Chicken (缽缽雞)Sichuan-style skewered snackLaunched 2024—
Collagen rice noodlesStaple foodPre-2021; ramp-up planned 2025—
Collagen brown sugar ginger drink / ginger teaBeverageUpgraded 2024—
Collagen oat drinksBeverage; production licence obtained 20222022; upgraded 2024—
Collagen oat porridge / oatmealBreakfast2023; upgraded 2024—
Collagen drinks (general)BeveragePre-2021—

Collagen Skincare Products

BrandProductsStatus
LuxiannaMasks, toners, multi-effect creams, collagen extracts, cleansers; existing production capabilityOngoing
COLL-FULL (高肌樂)Collagen masks and daily skincareLaunched ~2023
Collagen FamilySkincare rangeLaunched ~2024
coll-shineSkincare rangeLaunched ~2024

Pricing and revenue not publicly disclosed.

Polymer Collagen Medical Biomaterials

ProductDescription / specsRegulatory status (latest)Source
Medical collagen raw materialsProprietary extraction; endotoxin 0.01 EU/ml vs FDA 0.5 EU/ml benchmark; filed with state authorities; ISO13485/ISO22442 (EU) at Guangdong Victory and Wuzhou VictoryCommercial; revenue -31.5% in 1H2026 (tariffs/trade frictions)2026 Interim; FY2022 Results
Collagen bone filling biomaterials (artificial bone)Class III medical deviceClinical trials completed 2023; licence application pending/progressing (2024–2026)FY2023–FY2025 Results; 2026 Interim
Dental medical collagen spongeClass IIIClinical trials completed (FY2025); registration application in preparationFY2025 AR
Oral post-operative medical collagen spongeClass IIIEthics approved 2024; entering clinical stageFY2024 Results
Medical collagen dressing / traumatic (wound) dressingMedical devicePhysicochemical testing/animal trials (2024)FY2024 Results
In-vivo absorbable haemostatic dressingMedical deviceAnimal trials (2022)FY2022 Results
"Small beauty needle" (小美容針)Medical aesthetics injectablePre-clinical (2024)FY2024 Results
Band-aids (Type I device)Basic deviceTrial production successful (2022)FY2022 Results

Services

ServiceProviderDescription
Third-party food testingGuangxi Wuzhou Zhongguan Testing Technology ServicesTests 600+ indicators (restated from 800+ due to SAMR methodology change); issues officially recognised reports

Exited Products

Generic pharmaceuticals via Wuzhou Sanjian Pharmaceutical: marketing authorisations for 50 products assigned to Guangxi Weiwei Pharmaceutical (agreement 26 Oct 2022; completed FY2023; gain RMB39.7m). Healthcare products via associate Ferguson (Wuhan) Biotech: investment written down to nil by end-2024.

Financial Narrative

All figures RMB millions unless stated. Sources: FY2022 Results (FY2021–22), FY2023 Results (FY2023), FY2024 Results (FY2024; FY2023 restated comparatives), FY2025 Results and Annual Report (FY2025). Analyst-derived lines are labelled "(calc.)".

Income Statement

Notes: FY2021 revenue growth uses FY2020 revenue of RMB961.6m (FY2022 AR five-year summary). FY2023 admin expense is the restated comparative; the original FY2023 announcement showed RMB152.0m. EBITDA definitions differ from aggregators: TipRanks shows FY2024 EBITDA of RMB90.4m and FY2021 of RMB212.0m, versus our calc. of RMB135.8m and RMB268.3m, because aggregators exclude interest income and other items. FY2023 PBT includes the one-off RMB39.7m pharma-licence gain (after-tax ~RMB29.8m); excluding it, FY2023 attributable profit would have been ~RMB1.4m (company disclosure, FY2024 Results).

Margin Analysis

Revenue CAGR FY2021–FY2025 (calc.): -3.3% per annum (RMB1,168.1m → RMB1,023.3m). FY2022–FY2025 CAGR: -0.3%.

Cost of Sales Composition (disclosed)

Sources: FY2022–FY2025 Results (MD&A, cost of sales; Note 5).

Balance Sheet

Interim update (30 June 2026, 2026 Interim Results): total assets RMB2,674.3m; cash and bank balances RMB550.7m; pledged deposits RMB10.7m; bank borrowings RMB425.9m (all due within one year, unsecured, fixed 0.85%–2.35%); net cash RMB135.4m; inventories RMB856.6m; total equity RMB2,077.1m; debt-to-equity 20.7%.

Borrowing currency: FY2022 included US$28.6m and HK$105.0m loans (hedged by a forward contract); from FY2023 all borrowings were RMB-denominated. FY2025 borrowings carried fixed rates of 1.0%–2.2%.

The jump in investment properties in FY2025 (RMB30.8m → RMB156.2m) reflects transfer of right-of-use assets and PP&E to investment property with a RMB25.2m revaluation gain through OCI (FY2025 Results), which also explains part of the PP&E decline.

Cash Flow

Notes: FY2021 capex not identified in sources reviewed. FY2024 dividend actually paid in 2025 was RMB118.3m (2026 Interim, Note 9) versus RMB119.3m estimated at declaration. Dividends paid in FY2022–FY2024 approximated by amounts declared for the prior year. No buybacks in FY2021–FY2025 or 1H2026 (each report states no purchase of listed securities). 1H2026: OCF +RMB3.0m (vs -RMB188.3m in 1H2025), capex RMB11.7m; FY2026 capex guidance RMB120.0m; capital commitments RMB109.1m.

Ratios (analyst calculations unless noted)

ROIC caveat: EBIT includes bank interest income, so ROIC on operating assets is lower than shown (operating EBIT before other income was negative in FY2022, FY2023 and FY2025). The 1H2026 finished goods/WIP days were 292.1, implying the cash conversion cycle has not yet improved despite positive 1H2026 operating cash flow.

Trend Commentary

Revenue. Revenue has oscillated in a RMB1.0–1.2bn band for a decade after peaking above RMB1.6bn in 2012–2013 (aggregator data). The FY2021 high (RMB1,168.1m) reflected a post-COVID restocking bounce; FY2022 fell 11.6% on lockdowns and export logistics; FY2023 recovered 7.6% on volume (+9.0%) and exports (+16.9%); FY2024 fell 8.4% as customers paused during the S-series product transition; FY2025 was flat (+0.6%) only because the Group deliberately discounted legacy and trial-run inventory in the second half to release working capital. 1H2026 revenue rose 2.7% (mainland +4.9%), with S-series sales up 47%.

Gross margin. The structural break occurred in FY2022, when gross margin collapsed from 26.6% to 15.5% on raw-material, energy and logistics inflation. Margins then stalled at ~15–17% through FY2023–FY2024, before falling to 10.2% in FY2025 and 4.4% in 1H2026. Management's "underlying" margin, excluding inventory provisions, was 18.9% (FY2024), 14.8% (FY2025) and 14.6% (1H2026), so the business has also lost ~4 points of underlying margin through price concessions on legacy product and higher input costs (raw materials +8.8%, energy +6.3%, labour +8.7% in FY2025).

Operating profitability. Before other income, the core operation has been at or below breakeven since FY2022. Reported profits in FY2022–FY2024 were sustained largely by bank interest income (RMB27–46m/year), government grants and, in FY2023, the RMB39.7m pharma-licence gain. As cash balances shrank (from RMB1.36bn to RMB0.56bn of cash and deposits), interest income fell from RMB46.1m (FY2022) to RMB15.4m (FY2025), removing the cushion.

Tax. Effective tax rates are structurally inflated by PRC dividend withholding tax on upstream cash repatriation and losses in non-casing subsidiaries. FY2025 tax of RMB31.3m on a pre-tax loss arose from a one-off intra-group loan repayment funded by PRC dividends (profit warning, 16 March 2026). 1H2026 recorded a tax credit of RMB9.2m.

Balance sheet and cash. Net cash has fallen by RMB786m in four years (FY2021 RMB941.2m → FY2025 RMB155.1m; 30 Jun 2026 RMB135.4m), driven by (i) dividends of ~RMB560m paid in 2022–2025 against cumulative attributable profit of ~RMB12m over FY2022–FY2025, (ii) capex of ~RMB277m over FY2022–FY2025, and (iii) an inventory build of ~RMB413m from FY2021 to FY2025. Short-term bank debt rose from RMB240.3m to RMB425.9m between end-2024 and mid-2026. Equity has declined every year since FY2021.

Inflection points. (1) FY2022: margin collapse; (2) FY2024: product relaunch, inventory build and first negative operating cash flow; (3) FY2025: first net loss and dividend suspension; (4) 1H2026: operating cash flow turned marginally positive (+RMB3.0m) despite a wider loss, suggesting inventory liquidation is beginning to release cash.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (CNY Mn)

1,168.11,032.21,110.41,016.81,023.3

Revenue growth YoY (%)

21.5-11.67.6-8.40.6

Cost of sales (CNY Mn)

857.6871.7939.6845.7918.5

Gross profit (CNY Mn)

310.5160.5170.9171.1104.7

Other income and gains (CNY Mn)

53.662.3104.157.734.1

of which bank interest income (CNY Mn)

38.546.139.727.415.4

Selling & distribution (CNY Mn)

36.633.835.033.530.8

Administrative expenses (CNY Mn)

144.5153.1150.8131.1131.7

Operating profit before other income, calc. GP less S&D less admin (CNY Mn)

129.4-26.4-14.96.5-57.8

Finance costs (CNY Mn)

5.39.29.17.36.7

Profit before tax (CNY Mn)

163.035.767.944.1-35.3

Income tax (CNY Mn)

43.014.238.415.231.3

Effective tax rate (%)

26.439.856.534.5—

Profit for the year (CNY Mn)

120.021.529.528.9-66.7

Net income attributable to owners (CNY Mn)

122.723.631.226.7-69.8

D&A, PP&E plus right-of-use (CNY Mn)

100.0101.2101.084.477.4

EBIT, calc. PBT plus finance costs (CNY Mn)

168.344.977.051.4-28.6

EBITDA, calc. EBIT plus D&A (CNY Mn)

268.3146.1178.0135.848.8

EBITDA ex bank interest income, calc. (CNY Mn)

229.8100.0138.3108.433.4

EPS basic and diluted (MYR Bn cents)

3.80.71.00.8-2.2

DPS final plus special (HK cents)

6.06.04.04.00.0

Inventory write-offs and provisions, net (CNY Mn)

-1.823.62.021.046.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

26.615.515.416.810.2

Gross margin ex inventory provisions (%)

———18.914.8

Operating margin before other income, calc. (%)

11.1-2.6-1.30.6-5.6

EBITDA margin, calc. (%)

23.014.216.013.44.8

Pre-tax margin (%)

14.03.56.14.3-3.5

Net margin attributable (%)

10.52.32.82.6-6.8

S&D as % of revenue

3.13.33.13.33.0

Admin as % of revenue

12.414.813.612.912.9

Key Financials

MetricFY2022FY2023FY2024FY2025

Raw materials cost (CNY Mn)

434.5469.6381.7415.1

Energy charges (CNY Mn)

162.7182.4172.9183.7

Direct labour (CNY Mn)

139.9155.0148.6161.5

Total employee benefit expense, P&L (CNY Mn)

185.6219.5236.1261.2

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (CNY Mn)

3,312.13,354.42,957.32,829.22,764.6

Cash and cash equivalents (CNY Mn)

998.9954.0824.0503.8533.8

Cash plus pledged plus time deposits (CNY Mn)

1,359.41,363.61,024.0646.3555.3

Short-term bank borrowings (CNY Mn)

418.2535.2272.8240.3400.2

Long-term bank borrowings (CNY Mn)

0.00.00.00.00.0

Lease liabilities total (CNY Mn)

9.85.54.57.75.7

Net cash, company definition (CNY Mn)

941.2828.4751.2406.0155.1

Net debt, calc. (CNY Mn)

-941.2-828.4-751.2-406.0-155.1

Inventories (CNY Mn)

422.3496.3504.5814.0835.5

Trade and bills receivables (CNY Mn)

190.3207.0182.7158.8190.2

Trade and bills payables (CNY Mn)

49.085.0101.7111.284.9

Property, plant and equipment (CNY Mn)

1,056.21,006.01,003.5977.4826.2

Investment properties (CNY Mn)

17.015.914.230.8156.2

Goodwill and intangibles (CNY Mn)

0.00.00.00.00.0

Total liabilities, calc. (CNY Mn)

656.5835.0581.1536.5638.3

Total equity (CNY Mn)

2,655.62,519.42,376.22,292.72,126.3

Equity attributable to owners (CNY Mn)

2,658.22,524.22,382.62,296.92,126.7

Working capital, net current assets (CNY Mn)

1,110.91,164.01,076.31,031.2994.3

Book value per share, calc. (MYR Bn)

0.820.780.740.710.66

Cash Flow and Returns & Leverage Ratios (%)

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (CNY Mn)

179.7106.0176.4-143.3-88.5

Capital expenditure (CNY Mn)

—50.3110.787.828.8

Free cash flow, calc. OCF less capex (CNY Mn)

—55.765.7-231.1-117.3

Dividends declared for the year (CNY Mn)

157.6168.8117.2119.30.0

Dividends paid in the year (CNY Mn)

—157.6168.8117.2118.3

Payout ratio of declared dividend to attributable profit, calc. (%)

1287153764470

Share buybacks (CNY Mn)

0.00.00.00.00.0

Investing cash flow (CNY Mn)

—44.8298.1161.781.6

Financing cash flow (CNY Mn)

—-71.0-455.2-162.130.8

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2021FY2022FY2023FY2024FY2025

ROE, attributable profit over average total equity (%)

4.60.91.31.1-3.2

ROA, profit over average total assets (%)

3.70.60.91.0-2.4

ROIC, EBIT times 0.85 over equity plus debt less cash (%)

8.32.34.02.3-1.2

Current ratio (x)

2.802.442.943.032.61

Debt to equity, company definition (%)

16.121.511.710.819.1

Net debt to EBITDA (x)

-3.5-5.7-4.2-3.0-3.2

Interest coverage, EBIT over finance cost (x)

31.54.98.57.0-4.3

Asset turnover, revenue over average total assets (x)

0.360.310.350.350.37

Raw material inventory days (company)

37.439.837.761.165.7

Finished goods and WIP inventory days (company)

159.6152.5156.7223.4262.0

Trade receivable days (company)

56.070.264.061.362.2

Trade payable days (company)

87.151.072.167.078.0

Cash conversion cycle, calc. sum of inventory days plus receivable days less payable days

165.9211.5186.3278.8311.9

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

Chinese mainland revenue (CNY Mn)

1,056.9899.0961.6883.4900.0

Asia excluding Chinese mainland revenue (CNY Mn)

60.967.599.185.985.7

Other countries/regions revenue (CNY Mn)

50.365.749.847.537.6

Total revenue (CNY Mn)

1,168.11,032.21,110.41,016.81,023.3

Growth and mix (%)

Growth and mix (%)FY2022FY2023FY2024FY2025

Chinese mainland growth YoY (%)

-14.97.0-8.11.9

Asia ex mainland growth YoY (%)

10.746.8-13.3-0.3

Other regions growth YoY (%)

30.8-24.2-4.6-20.9

Chinese mainland share of revenue (%)

87.186.686.987.9

Asia ex mainland share of revenue (%)

6.58.98.48.4

Other regions share of revenue (%)

6.44.54.73.7

Revenue by Region (1H2025–1H2026)

Region (half-year)1H20251H2026

Chinese mainland revenue (CNY Mn)

387.6406.6

Asia excluding mainland revenue (CNY Mn)

36.229.9

Other countries/regions revenue (CNY Mn)

20.119.4

Capital Markets

ItemValueSource

IPO price (13 Oct 2009)

HK$3.10 (top of HK$2.10–3.10 range)

FinanceAsia

Year-end 2025 market cap

HK$856.1m (≈HK$0.265/share, calc.)

FY2025 AR

Latest indicative price

~HK$0.18–0.185 (snapshot date not stamped)

Simply Wall St; etnet

Latest indicative market cap

~HK$597.6m

Simply Wall St

1-year price change

~-36% (aggregator)

Simply Wall St

Since IPO

~-94% (calc. from HK$3.10 to ~HK$0.185)

calc.

Mid-Oct 2025 reference

HK$0.28; market cap HK$904.5m; 12-month range HK$0.25–0.34

TipRanks (Oct 2025)

Beta

~0.59 (aggregator)

Snowball Analytics

Valuation Multiples

MultipleShenguanViscofanComment

P/E (TTM)

n.m. (loss)

n.d. in sources reviewed

—

EV/EBITDA (TTM)

n.m. (TTM EBITDA near zero or negative)

——

EV/Sales (TTM)

~0.40x

—

Deep discount

P/B

~0.26x

—

Trades at ~1/4 of book value

Dividend yield

0% (suspended)

—

FY2024 payout was HK4.0c (yield ~14% at Oct-2025 prices)

Per-Share Data and Dividends & Capital Returns

MetricFY2021FY2022FY2023FY2024FY2025

Final dividend per share (HK cents)

2.02.02.02.00.0

Special final dividend per share (HK cents)

4.04.02.02.00.0

Total dividend per share (HK cents)

6.06.04.04.00.0

Total dividends declared (CNY Mn)

157.6168.8117.2119.30.0

Analyst Conclusions

Management Guidance

  • FY2026 capex ~RMB120m (casing line upgrades plus the Inner Mongolia base).

  • Stricter inventory control and higher-grade product yields in 2H2026.

  • Continued S-series and halal expansion; compound-ingredient commercialisation.

  • Continued pursuit of the Class III artificial bone licence and the dental collagen sponge application.

  • No revenue, margin or profit guidance.

Consensus Expectations

None available (no meaningful sell-side coverage).

Bull Case

  1. Provisions are finite and front-loaded. The overhang stems from 2022–2024 trial production. With RMB46.4m (FY2025) plus RMB46.7m (1H2026) already provided, and underlying gross margin still ~14.6%, a clean-up by 2027 could restore gross profit toward RMB150m on flat revenue — enough for operating breakeven or better.

  2. Mix shift is real. S-series rose from 31% to 43% of casing sales in a year (+47% in value). If the new high-end lines and Inner Mongolia base relieve the stated capacity shortfall, mix-driven margin expansion could compound.

  3. Asset backing. At ~0.26x book with net cash and RMB826m of PP&E, the market implies large further write-downs; controlling-shareholder buying (Oct 2025) and potential reinstatement of dividends offer re-rating optionality.

Bear Case

  1. Structural margin decline. Underlying gross margin fell from 18.9% to 14.8% to 14.6% even before provisions, as raw materials, energy and labour inflate faster than price; competition from Viscofan-class players and domestic producers may cap pricing permanently.

  2. Balance-sheet erosion. Net cash fell from RMB941m (FY2021) to RMB135m (1H2026) while short-term debt rose; RMB120m of 2026 capex plus continued losses could tip the Group into net debt within 12–18 months.

  3. Governance and capital allocation. A history of paying dividends far above earnings (payout 376–715% in FY2022–FY2024), related-party raw-material supply (top supplier 67.7%), family-dominated management and failed diversification (pharma, associate) argue for a persistent governance discount.

Catalysts and Monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
Inner Mongolia land auction and formal contract2H2026–2027Binding agreement, capex phasing, funding
FY2026 results~Mar 2027Size of further inventory provisions; gross margin ex-provisions; OCF; dividend decision
Inventory and FG daysEach reportInventories below RMB800m; FG/WIP days falling from 292
S-series shareEach reportAbove 50% of casing sales
Net cash / debtEach reportWhether net cash stays positive
Medical device approvalsUnpredictableClass III artificial bone licence; dental sponge filing
Halal and export revenueEach reportReversal of 1H2026 Asia decline (-17.4%)
Energy and raw material costsOngoingElectricity tariffs; cattle-skin prices
GovernanceAGM 2027INED refresh; CEO appointment; related-party terms
Insider dealingOngoingFurther controlling-shareholder purchases

Analyst Verdict

Shenguan Holdings is a once-dominant industrial franchise now in the hardest phase of a turnaround it largely engineered itself. The 2023–2024 production-line rebuild and S-series relaunch were strategically sensible — the downstream sausage industry is clearly migrating toward larger-calibre, higher-quality, clean-label products, and Shenguan's new lines are winning share (43% of casing sales in 1H2026, up from 31%). But execution has been costly: trial-run and legacy inventory has forced roughly RMB93m of provisions in eighteen months, gross margin has collapsed to single digits, and the Group has posted consecutive losses. Underlying profitability, even excluding provisions, has also slipped, implying genuine pricing and cost pressure rather than a purely accounting problem.

The balance sheet, while still net cash, is no longer a fortress. Generous dividends funded from cash rather than earnings, combined with inventory build and capex, have consumed over RMB780m of net cash since FY2021, and the company now relies entirely on short-term bank lines. The suspension of the dividend in March 2026 was overdue and correct.

Valuation reflects deep scepticism: around a quarter of book value and roughly 0.4x EV/sales. That discount is partly warranted by governance features — a combined Chair/CEO, family members throughout management and the supply chain, long-serving INEDs and a history of value-destructive diversification. Yet the downside is cushioned by tangible assets, a founder who bought stock in late 2025, and a business that was generating RMB100–180m of OCF as recently as FY2022–FY2023.

Our assessment: speculative turnaround, high risk, monitor rather than accumulate until three conditions are met — inventory provisions clearly abate (gross margin back above 14% reported), operating cash flow is sustainably positive, and the Inner Mongolia project is funded without eroding net cash. If those materialise in FY2026–FY2027 results, the asset discount offers substantial re-rating potential; if not, further book-value erosion is likely.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAge (FY2025 AR)Board tenureBackground / educationFY2025 total remuneration (CNY K)

Ms. Zhou Yaxian

Chairman and President (ED); Chair, Nomination Committee

66

Director since 24 Feb 2009; Chairman since 19 Sep 2009

Founder; ~46 years in collagen casings; Central Party School economic management course; inventor on four national patents; State Council special allowance since 2008

3,598

Mr. Sha Junqi

Vice President (ED); President (since 1 Jan 2024) and Chairman (since 2 Sep 2025) of Shenguan Collagen

39

Since 31 May 2023

Son of Ms. Zhou; MSc Technopreneurship and Innovation, Nanyang Technological University (2015); runs Guangzhou trading arm; director of associate Ferguson (Wuhan)

1,428

Mr. Mo Yunxi

Vice President (ED); quality control and product development

57

Since 16 May 2012

Food Engineering, Tianjin College of Commerce (1990); senior food engineer; Deputy GM of Shenguan Collagen since 2004

1,536

Mr. Li Chenglin

Vice President (ED); corporate management, statistics, legal

54

Since 31 May 2023; VP of Company since 24 Mar 2025

Guangxi University; BBA (Dongbei University of Finance and Economics programme); senior economist; ex-Board Secretary, Guangxi Wuzhou Pine Resin

941

Mr. Ru Xiquan

Former VP (ED); finance and treasury

63

19 Sep 2009 – retired 6 Jun 2025

Chief Accountant of Shenguan Collagen since 2004

732 (part-year)

Dato' Sri Low Jee Keong

Non-executive Director

60

Since 19 Sep 2009

Co-founder; Malaysia-based distributor (Exceltech); Datukship 2012

73

Mr. Tsui Yung Kwok

INED; Chair, Audit Committee

57

Since 19 Sep 2009 (>9 years)

B.Bus (Accounting), Curtin; MCG, HK PolyU; CFO and ED of Ju Teng International (3336.HK); INED of Cabbeen (2030.HK) and Intron Technology (1760.HK)

229

Mr. Meng Qinguo

INED; Chair, Remuneration Committee

68

Since 19 Sep 2009 (>9 years)

LLM and PhD (Law), Wuhan University; ex-Berkeley visiting scholar; INED of Vanho Securities

229

Mr. Zhou Xiaoxiong

INED

65

Since 31 May 2023

Renmin University; Tsinghua MBA; ex-President Zhongshan Securities; ex-Chairman J.P. Morgan Futures (2006–2021); INED China Boton (3318.HK), Sunwoda, Shenzhen Laibao

229

Executive Leadership Team

NameTitleAgeSinceResponsibilities / background

Mr. Ng Yuk Yeung

Vice President, Company Secretary (de facto CFO)

52

Joined Feb 2009; VP since 24 Mar 2023

HKU Computer Science; FCCA, HKICPA, CFA; ex-China Resources Enterprise (2002–2007); financial reporting, corporate finance, IR

Mr. Chen Yong

Vice President

58

1 Jun 2023

Pharmacy degree, Guangxi University of Chinese Medicine; ex-Wuzhou Zhongheng Group; medical collagen and medical device production, quality and marketing

Mr. Zhou Yuanzhong

Vice President

57

1 Jan 2024

Hunan University civil engineering; ex-Guangxi highway bureaus; ex-GM Wuzhou Huaguan Investment; admin, logistics, plant construction. Cousin of Ms. Zhou

Mr. Yu Yubin

Vice President

61

Dec 2024

Harbin Engineering University; National Model Worker (2010); ex-chief engineer, China Shipbuilding South China Marine Machinery; equipment innovation and technical renovation

Board & Management Changes

DateChangeContext

31 May 2023

Shi Guicheng retired as ED; Sha Junqi and Li Chenglin appointed EDs; Zhou Xiaoxiong appointed INED

Generational refresh

1 Jun 2023

Chen Yong appointed VP

Medical collagen focus

1 Jan 2024

Sha Junqi becomes President of Shenguan Collagen; Ms. Zhou retires as GM; Zhou Yuanzhong appointed VP

Succession

Dec 2024

Yu Yubin appointed VP

Equipment and automation drive

24 Mar 2025

Li Chenglin appointed VP of the Company

—

6 Jun 2025

Ru Xiquan retires as ED

Departure of long-time finance head

2 Sep 2025

Sha Junqi becomes Chairman of Shenguan Collagen; Ms. Zhou retires from that role

Operating-company control passes to second generation

5 Jun 2026

Sha Junqi, Li Chenglin and Tsui Yung Kwok retire by rotation and offer themselves for re-election at the 2026 AGM

—

Major Shareholders

HolderStakeNotesSource

Ms. Zhou Yaxian (via Shenguan Biology Science & Technology Investment Co. → Glories Site Ltd → Rich Top Future Ltd, plus Xian Sheng Ltd)

~50.50% (~1,631m shares) after buying 4.21m shares at ~HK$0.295 on 2 Oct 2025

Controlling shareholder. Earlier DI filings (2017) showed a deemed interest of 2,174.28m shares (66.7% of 3,259m then in issue), partly via Rich Top Future in which Glories Site held 65.45%. The difference versus ~50.5% is unexplained in sources reviewed; it may reflect a change in the deemed-interest calculation or a restructuring of Rich Top Future. Discrepancy flagged

itiger (HKEX DI data); HKEX DI Form DA20170717000132

Dato' Sri Low Jee Keong (via Wealthy Safe Management Ltd and Brighter Lane Ltd)

n.d. in sources reviewed

Described as having interests in Company shares via these vehicles

FY2025 AR

Rich Top Future Limited

Named parent by aggregator

Ultimate parent per stoxray

stoxray

Free float (approx.)

~49.5% or less

Derived from controlling stake

calc.

Competitive Landscape

Key Competitors

CompetitorHomeSegment overlapRevenue (latest available)Positioning vs ShenguanSource

Viscofan S.A.

Spain (BME: VIS)

Collagen, cellulose, fibrous, plastic casings; global #1

FY2025: €1,240m (+8.0%) per one source vs €1,252m per AR summary; EBITDA €296.1m (23.9% margin); net profit €147.6m vs €160m (sources conflict)

Global leader; diversified casing technologies; far higher margins; operates in China

getquin; sustainabilityreports.com

Devro (SARIA group)

UK

Collagen casings (edible and non-edible); global #2 in collagen

—

Strong in Western markets and gels; historically had a China plant

Analyst knowledge

ViskoTeepak

Poland/Finland

Cellulose, fibrous and some collagen casings

—

Tier-1 global player

Industry reports

Nippi Collagen / Nippi Inc.

Japan

Collagen casings; expanding North American capacity

—

Tier-1 in Japan/US

Industry reports

Kalle GmbH

Germany

Fibrous/textile/plastic casings

—

Indirect competitor (non-collagen)

Allied Market Research

Fibran Group

Spain

Collagen casings

—

Tier-2 regional

Industry reports

Oversea Casing Company

US

Natural and collagen casings distribution

—

Tier-2 US

Industry reports

DAT-Schaub (Danish Crown)

Denmark

Natural casings

—

Substitute supplier

Meticulous Research

Selo B.V.

Netherlands

Casings

—

Tier-2

Meticulous Research

Manufacturas Alduay; Gemcal Casings India; Rafviez

Spain/India

Casings

—

Regional

Allied Market Research

Domestic Chinese collagen casing producers

China

Low-end and mid-range casings

—

Price competition in mass market; not individually identified in sources reviewed

—

Natural casings (hog/sheep intestines)

Global

Substitute

—

Premium "natural" positioning; Shenguan's imitation-natural casings target this

FY2025 AR risk factors

Peer Comparison FY2025

MetricShenguan (0829.HK)Viscofan (VIS)Devro (SARIA)Nippi

Revenue

RMB1,023.3m (~€125m equivalent, indicative)

€1,240–1,252m

—

Not publicly disclosed (casing-level)

Revenue growth YoY

+0.6%

+8.0% (one source)

——

Gross margin

10.2%

n.d. for FY2025 (FY2024 aggregator ~68% on a different cost classification)

——

EBITDA margin

4.8% (calc.)

23.9%——

Net margin

-6.8%

~11.9–12.8%

——

R&D intensity

————

Net debt / EBITDA

Net cash

~0.5x

——

“—” = not publicly disclosed.

Company Snapshot

$142.3M

Revenue

2,793

Employees

1979

Founded

Causeway Bay, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Net-cash balance sheet: RMB135.4m net cash at 30 Jun 2026, all borrowings at fixed rates of 0.85%–2.35% (2026 Interim).
  • Scale capacity: ~7bn metres of casing capacity and ~300 lines after the 2023 rebuild (FY2023–FY2024 Results).
  • Product-refresh traction: S-series sales up 47% to RMB197m in 1H2026; share up from 31% to 43% (2026 Interim).
  • Low customer concentration risk now: no customer above 10% of revenue in FY2024–FY2025, versus two customers at ~30–34% combined in FY2021–FY2023 (Results Announcements).
  • Tax advantage: 15% CIT for Shenguan Collagen under the western-region policy (FY2025 Results, Note 7).
  • Technology/IP: 114 patents granted (77 valid) at FY2024; low-endotoxin collagen patented in China, the US and Taiwan (FY2023–FY2024 Results).
  • Founder alignment: chairman owns ~50.5% and bought shares in October 2025 (itiger/HKEX DI).

Weaknesses

  • Loss-making: attributable loss RMB69.8m (FY2025) and RMB44.9m (1H2026).
  • Margin erosion: gross margin 26.6% (FY2021) → 10.2% (FY2025) → 4.4% (1H2026).
  • Inventory overhang: inventories RMB856.6m (30 Jun 2026), about 2x FY2021; FG/WIP days 292 (1H2026).
  • Cash burn history: cumulative FCF of ≈-RMB348m in FY2024–FY2025 (calc.).
  • Governance: combined Chairman/President role, family relationships across board/management/suppliers, two INEDs with >16 years' tenure (FY2025 AR).
  • Diversification failure to date: non-casing businesses remain <10% of revenue after 5+ years; pharma exited; associate written off.

Opportunities

  • High-end capacity gap: management says demand for high-end S-series exceeds current capacity (FY2025 Chairman's Statement).
  • Clean-label regulation: GB 7718-2025 (effective 2027) and related standards support compound ingredients (2026 Interim).
  • Inner Mongolia base: ~RMB90m project near high-quality hides could lower raw-material and logistics costs (13 Aug 2026 announcement).
  • Halal exports: certifications obtained 2024–2025; "phased progress" in 1H2026.
  • Medical device approvals: Class III artificial bone and dental collagen sponge registrations would unlock higher-margin sales (FY2025 AR).
  • Inventory normalisation: if provisions abate, underlying gross margin of ~14.6–14.8% implies material recovery from the reported 4.4–10.2%.

Threats

  • Global incumbents: Viscofan's FY2025 revenue (~€1.24–1.25bn) is roughly 10x Shenguan's, with a 23.9% EBITDA margin, enabling price/innovation pressure.
  • Trade friction: medical biomaterial revenue -31.5% in 1H2026; "other regions" revenue -20.9% in FY2025.
  • Energy cost reform: 1H2026 energy charges +5.9% to RMB80.7m.
  • Raw-material concentration: top supplier 67.7% of FY2025 purchases; a supply disruption would halt production.
  • Substitutes: natural casings and alternative casing technologies (FY2025 AR risk factors).
  • Liquidity squeeze if losses persist: short-term debt rose to RMB425.9m (30 Jun 2026) against RMB561.3m of cash and deposits; 2026 capex guidance of RMB120m.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
24 Mar 2025FY2024 results: revenue RMB1,016.8m (-8.4%); profit RMB26.7m; final HK2.0c plus special HK2.0cLast profitable year; dividend maintained despite negative OCF
24 Mar 2025Li Chenglin appointed VP of the CompanyManagement depth
6 Jun 2025AGM; Ru Xiquan retires; Mo Yunxi, Dato' Sri Low and Zhou Xiaoxiong re-electedFinance veteran exits
~9 Jul 2025FY2024 dividends paid (RMB118.3m)Major cash outflow amid inventory build
13 Aug 2025Board meeting notice for interim resultsRoutine
25 Aug 20251H2025 results: revenue RMB443.9m (-1.9%); attributable loss RMB40.6m vs profit RMB8.2mFirst interim loss; weak meat demand cited
1H2025Withholding tax charge from intra-group loan repayment (RMB18.0m tax in 1H2025)Non-operating drag
2 Sep 2025Sha Junqi becomes Chairman of Shenguan CollagenSecond-generation control of the operating company
16 Sep 20252025 Interim Report publishedRoutine
2 Oct 2025Chairman Zhou buys 4.21m shares at ~HK$0.295; stake ~50.50%Insider buying signal
13 Oct 2025INED service contracts (Tsui, Meng) renewed for two yearsLong-tenure INEDs retained
3 Nov 2025Monthly return: no change in 3,230,480,000 sharesNo dilution or buybacks
FY2025Dental medical collagen sponge clinical trials completedPipeline milestone
FY2025"Shenguan" ranked among China's 500 most valuable brands (World Brand Laboratory); Guangxi Manufacturing Industry Champion Enterprise (2024–2026)Reputation
FY2025Principal drafter of T/CITS 396-2025 synthetic-biofood standardStandards positioning
16 Mar 2026Profit warning: FY2025 loss of RMB65–78m expected (operating loss RMB22–35m after tax plus withholding tax)Negative surprise; shares weak
18 Mar 2026Board meeting notice for FY2025 resultsRoutine
30 Mar 2026FY2025 results: revenue RMB1,023.3m (+0.6%); loss RMB69.8m; GM 10.2%; no final dividendDividend suspended after 16 years of payouts
30 Mar 2026Workforce Diversity Policy adopted; Dividend and Nomination Policies amendedGovernance update
29 Apr 2026FY2025 Annual Report publishedRoutine
5 Jun 2026AGM (Sha, Li, Tsui up for re-election)–
1H2026Electricity cost increases from national pricing-mechanism adjustment; raw-material supply fluctuationsCost headwind
1H2026Recognised as Guangxi "Contract-abiding and Creditworthy" enterprise; 2025 Guangxi Top 100 High-Tech EnterprisesReputation
1H2026Co-drafted T/CIET2367-2026 (safety evaluation of synthetic-biology strains for food) releasedStandards
1H2026Three technologies with Shaanxi University of Science and Technology enter patent applicationR&D
1H2026Medical biomaterial revenue -31.5% on trade frictions/tariffsDiversification setback
1H2026Halal business deployment makes phased progressNew export driver
13 Aug 2026Framework investment agreement for ~RMB90m Horinger (Inner Mongolia) projectCapacity and raw-material strategy
25 Aug 20261H2026 results: revenue RMB456.0m (+2.7%); loss RMB44.9m; GM 4.4%; OCF +RMB3.0m; net cash RMB135.4mLoss widens but cash flow stabilises
Aug 2026Headcount ~2,793 (vs 3,010 a year earlier)Automation/cost reduction

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from CNY 1,168.1 Mn in FY2021 to CNY 1,023.3 Mn in FY2025.
Shenguan Holdings (Group) Limited — Income Statement: Revenue & Gross Profit
Series (CNY Mn)FY2021FY2022FY2023FY2024FY2025
Revenue1,168.11,032.21,110.41,016.81,023.3
Cost of sales857.6871.7939.6845.7918.5
Gross profit310.5160.5170.9171.1104.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. FY2025 Annual Report (29 Apr 2026) (www1.hkexnews.hk)
  2. FY2025 Results Announcement (30 Mar 2026) (www1.hkexnews.hk)
  3. 2026 Interim Results Announcement (25 Aug 2026) (www1.hkexnews.hk)
  4. Board meeting notice (13 Aug 2026) (www1.hkexnews.hk)
  5. 2025 Interim Results Announcement (25 Aug 2025) (www1.hkexnews.hk)
  6. 2025 Interim Report (16 Sep 2025) (hkexnews.hk)
  7. FY2024 Results Announcement (24 Mar 2025) (www1.hkexnews.hk)
  8. FY2023 Results Announcement (26 Mar 2024) (www1.hkexnews.hk)
  9. FY2023 Annual Report (www1.hkexnews.hk)
  10. 2024 Interim Results (www1.hkexnews.hk)
  11. FY2022 Results Announcement (24 Mar 2023) (www1.hkexnews.hk)
  12. FY2022 Annual Report (www1.hkexnews.hk)
  13. FY2021 Annual Report (www1.hkexnews.hk)
  14. 2021 Interim Report (www1.hkexnews.hk)
  15. FY2009 Results Announcement (www1.hkexnews.hk)
  16. 2010 Interim Results (www1.hkexnews.hk)
  17. HKEX Disclosure of Interests (Zhou Yaxian), e.g. (di.hkex.com.hk)
  18. itiger news on FY2025 results, profit warning, 2025 interim, Inner Mongolia agreement, chairman share purchase · itiger.com · itiger.com · itiger.com · itiger.com
  19. 10jqka (Inner Mongolia agreement) (stock.10jqka.com.cn)
  20. FinanceAsia (2009 IPO) (financeasia.com)
  21. TipRanks (price, market cap, rating) (tipranks.com)
  22. Simply Wall St (price, market cap) (simplywall.st)
  23. etnet (balance-sheet history, quote) (etnet.com.hk)
  24. stoxray (long-run revenue/profit history, aggregator) (stoxray.com)
  25. TradingView (ADR ISIN) (tradingview.com)
  26. Viscofan FY2025 (secondary summaries) · sustainabilityreports.com
  27. Meticulous Research (collagen casings market) (meticulousresearch.com)
  28. Industry report summary (China CAGR, tiering) (docswell.com)

Primary (HKEXnews):

Secondary:

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.